OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 38
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 38
Showing 26-50 of 38 citing articles:
Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single Institution Case Series
Ashwathy Balachandran Pillai, Mahmoud Yousef, Abdelrahman Yousef, et al.
(2024)
Open Access | Times Cited: 1
Ashwathy Balachandran Pillai, Mahmoud Yousef, Abdelrahman Yousef, et al.
(2024)
Open Access | Times Cited: 1
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal Adenocarcinoma
Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Safety, Efficacy, and Biomarker Results of a Phase 1b/2 Study Combining the CD40 Agonist Mitazalimab with mFOLFIRINOX in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC); Results of the OPTIMIZE-1 Trial
Jean‐Luc Van Laethem, Ivan Borbath, Hans Prenen, et al.
(2024)
Closed Access
Jean‐Luc Van Laethem, Ivan Borbath, Hans Prenen, et al.
(2024)
Closed Access
Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials
Robin John Lester Imperial, Osama Mosalem, Umair Majeed, et al.
Clinical and Experimental Gastroenterology (2024) Vol. Volume 17, pp. 121-134
Open Access
Robin John Lester Imperial, Osama Mosalem, Umair Majeed, et al.
Clinical and Experimental Gastroenterology (2024) Vol. Volume 17, pp. 121-134
Open Access
Genomic determinants of biological aggressiveness and poor prognosis of pancreatic cancers: KRAS and beyond
Calogero Ciulla, Claudio Luchini
Expert Review of Molecular Diagnostics (2024) Vol. 24, Iss. 5, pp. 355-362
Closed Access
Calogero Ciulla, Claudio Luchini
Expert Review of Molecular Diagnostics (2024) Vol. 24, Iss. 5, pp. 355-362
Closed Access
Clinical and genomic features of classical and basal transcriptional subtypes in pancreatic cancer
Harshabad Singh, Joanne Xiu, Kevin S. Kapner, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 21, pp. 4932-4942
Closed Access
Harshabad Singh, Joanne Xiu, Kevin S. Kapner, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 21, pp. 4932-4942
Closed Access
Prognostic Role of Specific KRAS Mutations Detected in Aspiration and Liquid Biopsies from Patients with Pancreatic Cancer
Tereza Hálková, Bohuš Bunganič, Eva Traboulsi, et al.
Genes (2024) Vol. 15, Iss. 10, pp. 1302-1302
Open Access
Tereza Hálková, Bohuš Bunganič, Eva Traboulsi, et al.
Genes (2024) Vol. 15, Iss. 10, pp. 1302-1302
Open Access
Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single-Institution Case Series
Ashwathy Balachandran Pillai, Mahmoud Yousef, Abdelrahman Yousef, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3421-3421
Open Access
Ashwathy Balachandran Pillai, Mahmoud Yousef, Abdelrahman Yousef, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3421-3421
Open Access
Introduction to RAS biology
Channing J. Der, Frank McCormick
Elsevier eBooks (2024), pp. 1-36
Closed Access
Channing J. Der, Frank McCormick
Elsevier eBooks (2024), pp. 1-36
Closed Access
Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer
Sreejith Thrivikraman Nair, C Abhi, Kaladhar Kamalasanan, et al.
Molecular Pharmaceutics (2024)
Closed Access
Sreejith Thrivikraman Nair, C Abhi, Kaladhar Kamalasanan, et al.
Molecular Pharmaceutics (2024)
Closed Access
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
Bernhard Doleschal
memo - Magazine of European Medical Oncology (2024)
Open Access
Bernhard Doleschal
memo - Magazine of European Medical Oncology (2024)
Open Access
TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1‐Mediated Arachidonic Acid Metabolism
Xiaona Fan, Yisheng Dai, Chaohua Mo, et al.
Advanced Science (2024)
Open Access
Xiaona Fan, Yisheng Dai, Chaohua Mo, et al.
Advanced Science (2024)
Open Access
AI screening and molecular dynamic simulation-driven identification of novel inhibitors of TGFßR1 for pancreatic cancer therapy
Samvedna Singh, Kiran Bharat Lokhande, Aman Chandra Kaushik, et al.
Computational Biology and Chemistry (2024) Vol. 113, pp. 108262-108262
Closed Access
Samvedna Singh, Kiran Bharat Lokhande, Aman Chandra Kaushik, et al.
Computational Biology and Chemistry (2024) Vol. 113, pp. 108262-108262
Closed Access
